Sermorelin Dosing Protocol: GHRH Research Guide

Also known as: GHRH (1-29), Geref

hormonal

Research Reference Only

This information is for educational purposes only. Sermorelin is not FDA approved for human use. The protocols listed are summaries of published research studies and do not constitute medical advice. Always consult a licensed healthcare provider.

Overview

Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of growth hormone-releasing hormone. It stimulates the pituitary gland to produce and release growth hormone.

Mechanisms of Action

Binds to GHRH receptors in pituitary

Stimulates GH synthesis and secretion

Preserves normal feedback mechanisms

Does not suppress natural GH production

Research Protocols

The following protocols are summaries of published research studies. They are presented for educational purposes only and do not constitute medical advice.

Protocol Name	Source	Dose	Frequency	Duration	Route	Evidence	Link
Growth Hormone Deficiency Study	published study	0.3 mg	Daily	12 months	Subcutaneous	human

Important Warnings

Safety Considerations

Requires daily injections
Effects diminish if not taken at bedtime
May cause flushing or headache
Not as potent as direct GH administration